Whether two compounds are mechanistically compatible is a secondary question. The prior question is whether the problem each one is solving has been confirmed. This framework answers that.
For educational and research purposes only. This is not medical advice and is not human-use guidance. Consult a qualified professional before acting on anything here.
Start here
A stack of two compounds does not become more useful just because both are effective on their own. The gain from combining them depends on whether they address different problems through different receptor mechanisms, and whether each one has already shown a clear response in isolation.
The framework below condenses that into three questions in order. A No at any step stops the sequence. Reconfiguring is the next step at that point, not adding a second compound.
Different mechanisms does not mean a compound should be added. It only means it has the potential to be useful if the problem is correctly identified first.
Yes to all three means the mechanism argument for combining these compounds holds. That is the precondition, not the decision. The stack still needs the right timing, the right sequencing, and a confirmed problem on each side.
The sections below cover all four stack categories and what the confirmed problem looks like for each one.
Compound DiagnosticA No on pathways means the compounds share a receptor mechanism, so adding the second is redundant rather than additive. A No on problems means they are solving the same issue through different routes, which adds cost without adding a new lever. A No on solo response means one compound has not been established yet and the stack cannot be read accurately if it is.
Resolving the No is the step that determines whether a stack makes sense at all. The search engine covers each of these questions individually.
Ask the search engineFree — no payment required
The sections below cover additive, conditional, either/or, and redundant stacks with the specific compounds and confirmed conditions for each. Enter your email to unlock them. One step, no account needed.
No spam. Used only for research guide access and occasional protocol updates from Project Theo.
Part two
Additive stacks pass the compatibility test by their structure. Each compound uses a different receptor mechanism and addresses a different problem. Neither depends on what the other is finding, so they can run together without a conditional requirement first.
GHRH pathway — initiates pulse
Works through the GHRH receptor to initiate the GH pulse. DAC refers to Drug Affinity Complex, an attachment that extends half-life. The version without it keeps the release pattern closer to a natural pulse shape.
Ghrelin pathway — amplifies signal
Works through a separate receptor than CJC 1295. Because the two compounds use different pathways, the combined signal produces a sharper pulse than either one alone.
Two pathways — sharper combined pulse.
Local mechanism — site-specific
Acts at or near the site where it is applied. Its mechanism is local and site-specific, which makes it suited to targeted tissue contexts.
Systemic mechanism — circulating repair
Circulates and supports repair at a broader level. Local and systemic are different targets, which is the reason these two run together rather than one being chosen over the other.
Different targets — local and systemic run together.
Part three
The mechanism difference is real in both of these stacks. The confirmation requirement is not about whether the compounds are compatible. It is about whether the problem the addition is meant to address is actually present. Without that confirmation, the addition has no specific variable to act on.
Confirm lean mass loss first. Research suggests GH signaling may support lean mass retention. That is the lever this combination pulls. Confirming lean mass loss is the condition that determines whether the lever is relevant.
GH signaling side
Research suggests GH signaling may support lean mass retention. The GH stack is the mechanism that addresses this side of the equation when the condition is confirmed.
GLP-1 + GIP + glucagon
Controls intake and may influence energy expenditure via the glucagon receptor. The three-receptor mechanism is what distinguishes it from single and dual-receptor GLP-1 compounds.
Confirm metabolic slowdown first. Research suggests MOTS-c may support energy output under certain conditions. That is the lever this combination pulls. Confirming metabolic slowdown is the condition that determines whether adding MOTS-c has a problem to address.
Intake + possible output
Controls intake through GLP-1 and GIP receptors and may add an output effect through the glucagon receptor.
Mitochondrial signal
Research suggests MOTS-c may support energy output under certain conditions. The addition is evaluated after metabolic slowdown is confirmed, not before.
Part four
An either/or is not a stack. It is a diagnosis decision. Both MOTS-c and SS-31 work on mitochondrial function, but at different failure points. Running both before identifying which failure point exists adds cost without giving the protocol a lever that was not already there.
When: high activity, intake controlled
May support mitochondrial signaling related to energy demand and output. Research suggests this pathway is relevant where the demand side is active but the output signal is not responding in proportion.
When: stalled recovery, stimulant history
May support mitochondrial function when efficiency or recovery is impaired. Research suggests this pathway is relevant where past stimulant use or disrupted recovery patterns have affected mitochondrial efficiency.
The diagnostic step. Both target different mitochondrial failure points. Running both before identifying which failure point exists adds cost without leverage. Diagnose the pattern. Then pick the right tool.
Work through the conditions below and a pattern read will appear. It returns the pattern that fits the confirmed conditions, not a compound. Two conditions on one side must both be present before the pattern resolves. Saves to this device.
Nothing confirmed yet. Check the conditions above and a read will appear here.
Part five
A redundant stack sends two signals through the same receptor pathway. The feedback limitation on that pathway does not become more forgiving because two signals are arriving. Research suggests it becomes stronger, which is why the return on a same-pathway addition tends to be lower than on a compound that adds a new mechanism.
| Combination | Why this is redundant | What to run instead |
|---|---|---|
| Tesamorelin + CJC 1295 | Both are GHRH analogs. Same pathway, stronger feedback limitation, no new mechanism added, higher chance of diminishing returns. | Tesamorelin + Ipamorelin. Ipamorelin works through the ghrelin pathway rather than GHRH, which adds a mechanism rather than doubling one that is already present. |
| Combination | Why this is redundant | What to identify first |
|---|---|---|
| Semaglutide + Tirzepatide | Overlapping intake signals. In many cases a stall is not insufficient GLP-1. No new mechanism, higher chance of diminishing returns. | The actual variable limiting progress. In many cases the stall has a different cause, and adding a second GLP-1 compound does not address it. |
What a redundant stack reveals. A researcher who adds a compound through the same pathway and sees no change has confirmed the pathway is limited, not that the protocol needs a third compound. Identifying the actual variable is the step that follows a redundant result, not a further addition.
Next step
The Audit identifies where a protocol is limited and what the research suggests addressing first. If a stack question is part of it, the analysis works through the mechanism and confirms the pattern before any addition is evaluated.
